More flexible storage conditions for BioNTech/Pfizer’s COVID-19 vaccine EMA’s human medicines committee (CHMP) has recommended a change to the approved storage conditions of Comirnaty, the COVID-19 vaccine developed by BioNTech and Pfizer, that will facilitate the handling of the vaccine in vaccination centres across the European Union (EU). European Medicines Agency
No comments:
Post a Comment